Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy
The purpose of this study was to investigate the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on the progression of diabetic retinopathy (DR) in patients with type 2 diabetes. The medical records of 21 type 2 diabetic patients who used a SGLT2i and 71 patients with sulfonylurea (con...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2018/6807219 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560685685407744 |
|---|---|
| author | Eun Hyung Cho Se-Jun Park Seongwook Han Ji Hun Song Kihwang Lee Yoo-Ri Chung |
| author_facet | Eun Hyung Cho Se-Jun Park Seongwook Han Ji Hun Song Kihwang Lee Yoo-Ri Chung |
| author_sort | Eun Hyung Cho |
| collection | DOAJ |
| description | The purpose of this study was to investigate the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on the progression of diabetic retinopathy (DR) in patients with type 2 diabetes. The medical records of 21 type 2 diabetic patients who used a SGLT2i and 71 patients with sulfonylurea (control) were reviewed retrospectively. The severity of DR was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. Fewer patients who used a SGLT2i than control patients with sulfonylurea showed progression of DR based on ETDRS scale (44% versus 14%, P=0.014). Moreover, treatment with a SGLT2i was associated with a significantly lower risk of DR progression (P=0.021), and this effect remained significant after adjusting for the age, duration of diabetes, initial DR grade, and HbA1c level by propensity score matching (P=0.013). Treatment of type 2 diabetic patients with a SGLT2i slowed the progression of DR compared to sulfonylurea, which is independent of its effect on glycemic control. This study provides a foundation for further evaluation of the effect of SGLT2i on the progression of DR. |
| format | Article |
| id | doaj-art-a19fa95d749b4d2e898775d6a5a8613f |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-a19fa95d749b4d2e898775d6a5a8613f2025-02-03T01:26:55ZengWileyJournal of Diabetes Research2314-67452314-67532018-01-01201810.1155/2018/68072196807219Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic RetinopathyEun Hyung Cho0Se-Jun Park1Seongwook Han2Ji Hun Song3Kihwang Lee4Yoo-Ri Chung5Kong Eye Hospital, Seoul, Republic of KoreaDepartment of Cardiology, GangNeung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of KoreaDepartment of Ophthalmology, Ajou University School of Medicine, Suwon, Republic of KoreaDepartment of Ophthalmology, Ajou University School of Medicine, Suwon, Republic of KoreaDepartment of Ophthalmology, Ajou University School of Medicine, Suwon, Republic of KoreaDepartment of Ophthalmology, Ajou University School of Medicine, Suwon, Republic of KoreaThe purpose of this study was to investigate the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on the progression of diabetic retinopathy (DR) in patients with type 2 diabetes. The medical records of 21 type 2 diabetic patients who used a SGLT2i and 71 patients with sulfonylurea (control) were reviewed retrospectively. The severity of DR was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. Fewer patients who used a SGLT2i than control patients with sulfonylurea showed progression of DR based on ETDRS scale (44% versus 14%, P=0.014). Moreover, treatment with a SGLT2i was associated with a significantly lower risk of DR progression (P=0.021), and this effect remained significant after adjusting for the age, duration of diabetes, initial DR grade, and HbA1c level by propensity score matching (P=0.013). Treatment of type 2 diabetic patients with a SGLT2i slowed the progression of DR compared to sulfonylurea, which is independent of its effect on glycemic control. This study provides a foundation for further evaluation of the effect of SGLT2i on the progression of DR.http://dx.doi.org/10.1155/2018/6807219 |
| spellingShingle | Eun Hyung Cho Se-Jun Park Seongwook Han Ji Hun Song Kihwang Lee Yoo-Ri Chung Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy Journal of Diabetes Research |
| title | Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy |
| title_full | Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy |
| title_fullStr | Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy |
| title_full_unstemmed | Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy |
| title_short | Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy |
| title_sort | potent oral hypoglycemic agents for microvascular complication sodium glucose cotransporter 2 inhibitors for diabetic retinopathy |
| url | http://dx.doi.org/10.1155/2018/6807219 |
| work_keys_str_mv | AT eunhyungcho potentoralhypoglycemicagentsformicrovascularcomplicationsodiumglucosecotransporter2inhibitorsfordiabeticretinopathy AT sejunpark potentoralhypoglycemicagentsformicrovascularcomplicationsodiumglucosecotransporter2inhibitorsfordiabeticretinopathy AT seongwookhan potentoralhypoglycemicagentsformicrovascularcomplicationsodiumglucosecotransporter2inhibitorsfordiabeticretinopathy AT jihunsong potentoralhypoglycemicagentsformicrovascularcomplicationsodiumglucosecotransporter2inhibitorsfordiabeticretinopathy AT kihwanglee potentoralhypoglycemicagentsformicrovascularcomplicationsodiumglucosecotransporter2inhibitorsfordiabeticretinopathy AT yoorichung potentoralhypoglycemicagentsformicrovascularcomplicationsodiumglucosecotransporter2inhibitorsfordiabeticretinopathy |